Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry
•Particle therapy for patients with operable early-stage lung cancer has demonstrated good progression free and overall survival.•Toxicity was very mild, with Grade 3 toxicity occurring in 1.5 % of patients.•Type of particle therapy had no effect on overall survival or progression free survival. To...
Gespeichert in:
| Veröffentlicht in: | Radiotherapy and oncology 2024-09, Vol.198, p.110385, Article 110385 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 110385 |
| container_title | Radiotherapy and oncology |
| container_volume | 198 |
| creator | Harada, Hideyuki Suefuji, Hiroaki Mori, Keita Ishikawa, Hitoshi Nakamura, Masaki Tokumaru, Sunao Murakami, Masao Ogino, Takashi Iwata, Hiromitsu Tatebe, Hitoshi Kubo, Nobuteru Waki, Takahiro Yoshida, Daisaku Nakamura, Masatoshi Hashimoto, Takayuki Araya, Masayuki Nakajima, Mio Nakayama, Haruhiko Satouchi, Miyako Shioyama, Yoshiyuki |
| description | •Particle therapy for patients with operable early-stage lung cancer has demonstrated good progression free and overall survival.•Toxicity was very mild, with Grade 3 toxicity occurring in 1.5 % of patients.•Type of particle therapy had no effect on overall survival or progression free survival.
To investigate the toxicity and survival outcomes of proton and carbon ion radiotherapy for patients with operable early-stage lung cancer who are eligible for lobectomy.
This multicenter nationwide prospective cohort study included patients with operable early-stage lung cancer. Proton and carbon ion radiotherapy was performed according to the schedule stipulated in the unified treatment policy. Progression-free survival (PFS), overall survival (OS) and treatment-related toxicities were evaluated.
A total of 274 patients were enrolled and included in efficacy and safety analyses. The most common tumor type was adenocarcinoma (44 %), while 105 cases (38 %) were not histologically confirmed or diagnosed clinically. Overall, 250 (91 %) of the 274 patients had tumors that were peripherally situated, while 138 (50 %) and 136 (50 %) patients were treated by proton and carbon ion radiotherapy, respectively. The median follow-up time for all censored patients was 42.8 months (IQR 36.7–49.0). Grade 3 or severe treatment-related toxicity was observed in 4 cases (1.5 %). Three-year PFS was 80.5 % (95 % CI: 75.7 %–85.5 %) and OS was 92.5 % (95 % CI: 89.3 %–95.8 %). Pathological confirmation and clinical stage were factors significantly associated with PFS, while tumor location and particle-ion type were not. Meanwhile, clinical stage was significantly associated with OS, but pathological confirmation, tumor location, and particle-ion type were not.
Particle therapy for operable early-stage lung cancer resulted in excellent 3-year OS and PFS in each subset. In this disease context, proton and carbon ion beam therapies are feasible alternatives to curative surgery. |
| doi_str_mv | 10.1016/j.radonc.2024.110385 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3070839139</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167814024006558</els_id><sourcerecordid>3070839139</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-834aa3598afdbdb419b472ba3891e3938503ef43456eba69e381f4e5126434cb3</originalsourceid><addsrcrecordid>eNp9kE9LxDAQxYMouq5-A5EcvXRNmuw2RRBk8R8IetBzSNLpmqXb1KRV9ts70tWjh5BhePPmzY-QM85mnPHF5XoWTRVaN8tZLmecM6Hme2TCVVFmTKlin0xQVmSKS3ZEjlNaM8ZyJopDciRUyXhRsAlZv8TQh5aatqLORIulx4fWPvTvEE23pXWINHRY2wYomNhss9SbFdBmaFc41TqIV9TQLobUgev9J9DW9Ojz5SugEVY-9XF7Qg5q0yQ43f1T8nZ3-7p8yJ6e7x-XN0-ZE5z3mRLSGDEvlakrW1nJSyuL3BrMzEGUeCUTUEsh5wuwZlGCULyWMOf5ApvOiim5GH0xz8cAqdcbnxw0jWkhDEkLVjAlSo5eUyJHqcPoKUKtu-g3Jm41Z_qHsl7rkbL-oaxHyjh2vtsw2A1Uf0O_WFFwPQoA7_z0EHVyHpBT5SMC0lXw_2_4Bh0QkMI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3070839139</pqid></control><display><type>article</type><title>Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Harada, Hideyuki ; Suefuji, Hiroaki ; Mori, Keita ; Ishikawa, Hitoshi ; Nakamura, Masaki ; Tokumaru, Sunao ; Murakami, Masao ; Ogino, Takashi ; Iwata, Hiromitsu ; Tatebe, Hitoshi ; Kubo, Nobuteru ; Waki, Takahiro ; Yoshida, Daisaku ; Nakamura, Masatoshi ; Hashimoto, Takayuki ; Araya, Masayuki ; Nakajima, Mio ; Nakayama, Haruhiko ; Satouchi, Miyako ; Shioyama, Yoshiyuki</creator><creatorcontrib>Harada, Hideyuki ; Suefuji, Hiroaki ; Mori, Keita ; Ishikawa, Hitoshi ; Nakamura, Masaki ; Tokumaru, Sunao ; Murakami, Masao ; Ogino, Takashi ; Iwata, Hiromitsu ; Tatebe, Hitoshi ; Kubo, Nobuteru ; Waki, Takahiro ; Yoshida, Daisaku ; Nakamura, Masatoshi ; Hashimoto, Takayuki ; Araya, Masayuki ; Nakajima, Mio ; Nakayama, Haruhiko ; Satouchi, Miyako ; Shioyama, Yoshiyuki</creatorcontrib><description>•Particle therapy for patients with operable early-stage lung cancer has demonstrated good progression free and overall survival.•Toxicity was very mild, with Grade 3 toxicity occurring in 1.5 % of patients.•Type of particle therapy had no effect on overall survival or progression free survival.
To investigate the toxicity and survival outcomes of proton and carbon ion radiotherapy for patients with operable early-stage lung cancer who are eligible for lobectomy.
This multicenter nationwide prospective cohort study included patients with operable early-stage lung cancer. Proton and carbon ion radiotherapy was performed according to the schedule stipulated in the unified treatment policy. Progression-free survival (PFS), overall survival (OS) and treatment-related toxicities were evaluated.
A total of 274 patients were enrolled and included in efficacy and safety analyses. The most common tumor type was adenocarcinoma (44 %), while 105 cases (38 %) were not histologically confirmed or diagnosed clinically. Overall, 250 (91 %) of the 274 patients had tumors that were peripherally situated, while 138 (50 %) and 136 (50 %) patients were treated by proton and carbon ion radiotherapy, respectively. The median follow-up time for all censored patients was 42.8 months (IQR 36.7–49.0). Grade 3 or severe treatment-related toxicity was observed in 4 cases (1.5 %). Three-year PFS was 80.5 % (95 % CI: 75.7 %–85.5 %) and OS was 92.5 % (95 % CI: 89.3 %–95.8 %). Pathological confirmation and clinical stage were factors significantly associated with PFS, while tumor location and particle-ion type were not. Meanwhile, clinical stage was significantly associated with OS, but pathological confirmation, tumor location, and particle-ion type were not.
Particle therapy for operable early-stage lung cancer resulted in excellent 3-year OS and PFS in each subset. In this disease context, proton and carbon ion beam therapies are feasible alternatives to curative surgery.</description><identifier>ISSN: 0167-8140</identifier><identifier>ISSN: 1879-0887</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/j.radonc.2024.110385</identifier><identifier>PMID: 38901770</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Aged ; Carbon ; Female ; Heavy Ion Radiotherapy - adverse effects ; Heavy Ion Radiotherapy - methods ; Humans ; Lung cancer ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - radiotherapy ; Male ; Middle Aged ; National registry ; Neoplasm Staging ; Operable ; Particle therapy ; Prospective Studies ; Proton ; Proton Therapy - adverse effects ; Proton Therapy - methods ; Radiotherapy ; Registries</subject><ispartof>Radiotherapy and oncology, 2024-09, Vol.198, p.110385, Article 110385</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c311t-834aa3598afdbdb419b472ba3891e3938503ef43456eba69e381f4e5126434cb3</cites><orcidid>0000-0002-8529-5420 ; 0000-0002-0626-8142 ; 0000-0001-5276-3665 ; 0000-0002-4431-8892 ; 0000-0002-4037-1688 ; 0000-0001-9809-9800 ; 0000-0001-6450-3027 ; 0000-0002-4947-7665</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167814024006558$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38901770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harada, Hideyuki</creatorcontrib><creatorcontrib>Suefuji, Hiroaki</creatorcontrib><creatorcontrib>Mori, Keita</creatorcontrib><creatorcontrib>Ishikawa, Hitoshi</creatorcontrib><creatorcontrib>Nakamura, Masaki</creatorcontrib><creatorcontrib>Tokumaru, Sunao</creatorcontrib><creatorcontrib>Murakami, Masao</creatorcontrib><creatorcontrib>Ogino, Takashi</creatorcontrib><creatorcontrib>Iwata, Hiromitsu</creatorcontrib><creatorcontrib>Tatebe, Hitoshi</creatorcontrib><creatorcontrib>Kubo, Nobuteru</creatorcontrib><creatorcontrib>Waki, Takahiro</creatorcontrib><creatorcontrib>Yoshida, Daisaku</creatorcontrib><creatorcontrib>Nakamura, Masatoshi</creatorcontrib><creatorcontrib>Hashimoto, Takayuki</creatorcontrib><creatorcontrib>Araya, Masayuki</creatorcontrib><creatorcontrib>Nakajima, Mio</creatorcontrib><creatorcontrib>Nakayama, Haruhiko</creatorcontrib><creatorcontrib>Satouchi, Miyako</creatorcontrib><creatorcontrib>Shioyama, Yoshiyuki</creatorcontrib><title>Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>•Particle therapy for patients with operable early-stage lung cancer has demonstrated good progression free and overall survival.•Toxicity was very mild, with Grade 3 toxicity occurring in 1.5 % of patients.•Type of particle therapy had no effect on overall survival or progression free survival.
To investigate the toxicity and survival outcomes of proton and carbon ion radiotherapy for patients with operable early-stage lung cancer who are eligible for lobectomy.
This multicenter nationwide prospective cohort study included patients with operable early-stage lung cancer. Proton and carbon ion radiotherapy was performed according to the schedule stipulated in the unified treatment policy. Progression-free survival (PFS), overall survival (OS) and treatment-related toxicities were evaluated.
A total of 274 patients were enrolled and included in efficacy and safety analyses. The most common tumor type was adenocarcinoma (44 %), while 105 cases (38 %) were not histologically confirmed or diagnosed clinically. Overall, 250 (91 %) of the 274 patients had tumors that were peripherally situated, while 138 (50 %) and 136 (50 %) patients were treated by proton and carbon ion radiotherapy, respectively. The median follow-up time for all censored patients was 42.8 months (IQR 36.7–49.0). Grade 3 or severe treatment-related toxicity was observed in 4 cases (1.5 %). Three-year PFS was 80.5 % (95 % CI: 75.7 %–85.5 %) and OS was 92.5 % (95 % CI: 89.3 %–95.8 %). Pathological confirmation and clinical stage were factors significantly associated with PFS, while tumor location and particle-ion type were not. Meanwhile, clinical stage was significantly associated with OS, but pathological confirmation, tumor location, and particle-ion type were not.
Particle therapy for operable early-stage lung cancer resulted in excellent 3-year OS and PFS in each subset. In this disease context, proton and carbon ion beam therapies are feasible alternatives to curative surgery.</description><subject>Aged</subject><subject>Carbon</subject><subject>Female</subject><subject>Heavy Ion Radiotherapy - adverse effects</subject><subject>Heavy Ion Radiotherapy - methods</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>National registry</subject><subject>Neoplasm Staging</subject><subject>Operable</subject><subject>Particle therapy</subject><subject>Prospective Studies</subject><subject>Proton</subject><subject>Proton Therapy - adverse effects</subject><subject>Proton Therapy - methods</subject><subject>Radiotherapy</subject><subject>Registries</subject><issn>0167-8140</issn><issn>1879-0887</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9LxDAQxYMouq5-A5EcvXRNmuw2RRBk8R8IetBzSNLpmqXb1KRV9ts70tWjh5BhePPmzY-QM85mnPHF5XoWTRVaN8tZLmecM6Hme2TCVVFmTKlin0xQVmSKS3ZEjlNaM8ZyJopDciRUyXhRsAlZv8TQh5aatqLORIulx4fWPvTvEE23pXWINHRY2wYomNhss9SbFdBmaFc41TqIV9TQLobUgev9J9DW9Ojz5SugEVY-9XF7Qg5q0yQ43f1T8nZ3-7p8yJ6e7x-XN0-ZE5z3mRLSGDEvlakrW1nJSyuL3BrMzEGUeCUTUEsh5wuwZlGCULyWMOf5ApvOiim5GH0xz8cAqdcbnxw0jWkhDEkLVjAlSo5eUyJHqcPoKUKtu-g3Jm41Z_qHsl7rkbL-oaxHyjh2vtsw2A1Uf0O_WFFwPQoA7_z0EHVyHpBT5SMC0lXw_2_4Bh0QkMI</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Harada, Hideyuki</creator><creator>Suefuji, Hiroaki</creator><creator>Mori, Keita</creator><creator>Ishikawa, Hitoshi</creator><creator>Nakamura, Masaki</creator><creator>Tokumaru, Sunao</creator><creator>Murakami, Masao</creator><creator>Ogino, Takashi</creator><creator>Iwata, Hiromitsu</creator><creator>Tatebe, Hitoshi</creator><creator>Kubo, Nobuteru</creator><creator>Waki, Takahiro</creator><creator>Yoshida, Daisaku</creator><creator>Nakamura, Masatoshi</creator><creator>Hashimoto, Takayuki</creator><creator>Araya, Masayuki</creator><creator>Nakajima, Mio</creator><creator>Nakayama, Haruhiko</creator><creator>Satouchi, Miyako</creator><creator>Shioyama, Yoshiyuki</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8529-5420</orcidid><orcidid>https://orcid.org/0000-0002-0626-8142</orcidid><orcidid>https://orcid.org/0000-0001-5276-3665</orcidid><orcidid>https://orcid.org/0000-0002-4431-8892</orcidid><orcidid>https://orcid.org/0000-0002-4037-1688</orcidid><orcidid>https://orcid.org/0000-0001-9809-9800</orcidid><orcidid>https://orcid.org/0000-0001-6450-3027</orcidid><orcidid>https://orcid.org/0000-0002-4947-7665</orcidid></search><sort><creationdate>202409</creationdate><title>Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry</title><author>Harada, Hideyuki ; Suefuji, Hiroaki ; Mori, Keita ; Ishikawa, Hitoshi ; Nakamura, Masaki ; Tokumaru, Sunao ; Murakami, Masao ; Ogino, Takashi ; Iwata, Hiromitsu ; Tatebe, Hitoshi ; Kubo, Nobuteru ; Waki, Takahiro ; Yoshida, Daisaku ; Nakamura, Masatoshi ; Hashimoto, Takayuki ; Araya, Masayuki ; Nakajima, Mio ; Nakayama, Haruhiko ; Satouchi, Miyako ; Shioyama, Yoshiyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-834aa3598afdbdb419b472ba3891e3938503ef43456eba69e381f4e5126434cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Carbon</topic><topic>Female</topic><topic>Heavy Ion Radiotherapy - adverse effects</topic><topic>Heavy Ion Radiotherapy - methods</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>National registry</topic><topic>Neoplasm Staging</topic><topic>Operable</topic><topic>Particle therapy</topic><topic>Prospective Studies</topic><topic>Proton</topic><topic>Proton Therapy - adverse effects</topic><topic>Proton Therapy - methods</topic><topic>Radiotherapy</topic><topic>Registries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harada, Hideyuki</creatorcontrib><creatorcontrib>Suefuji, Hiroaki</creatorcontrib><creatorcontrib>Mori, Keita</creatorcontrib><creatorcontrib>Ishikawa, Hitoshi</creatorcontrib><creatorcontrib>Nakamura, Masaki</creatorcontrib><creatorcontrib>Tokumaru, Sunao</creatorcontrib><creatorcontrib>Murakami, Masao</creatorcontrib><creatorcontrib>Ogino, Takashi</creatorcontrib><creatorcontrib>Iwata, Hiromitsu</creatorcontrib><creatorcontrib>Tatebe, Hitoshi</creatorcontrib><creatorcontrib>Kubo, Nobuteru</creatorcontrib><creatorcontrib>Waki, Takahiro</creatorcontrib><creatorcontrib>Yoshida, Daisaku</creatorcontrib><creatorcontrib>Nakamura, Masatoshi</creatorcontrib><creatorcontrib>Hashimoto, Takayuki</creatorcontrib><creatorcontrib>Araya, Masayuki</creatorcontrib><creatorcontrib>Nakajima, Mio</creatorcontrib><creatorcontrib>Nakayama, Haruhiko</creatorcontrib><creatorcontrib>Satouchi, Miyako</creatorcontrib><creatorcontrib>Shioyama, Yoshiyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harada, Hideyuki</au><au>Suefuji, Hiroaki</au><au>Mori, Keita</au><au>Ishikawa, Hitoshi</au><au>Nakamura, Masaki</au><au>Tokumaru, Sunao</au><au>Murakami, Masao</au><au>Ogino, Takashi</au><au>Iwata, Hiromitsu</au><au>Tatebe, Hitoshi</au><au>Kubo, Nobuteru</au><au>Waki, Takahiro</au><au>Yoshida, Daisaku</au><au>Nakamura, Masatoshi</au><au>Hashimoto, Takayuki</au><au>Araya, Masayuki</au><au>Nakajima, Mio</au><au>Nakayama, Haruhiko</au><au>Satouchi, Miyako</au><au>Shioyama, Yoshiyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>2024-09</date><risdate>2024</risdate><volume>198</volume><spage>110385</spage><pages>110385-</pages><artnum>110385</artnum><issn>0167-8140</issn><issn>1879-0887</issn><eissn>1879-0887</eissn><abstract>•Particle therapy for patients with operable early-stage lung cancer has demonstrated good progression free and overall survival.•Toxicity was very mild, with Grade 3 toxicity occurring in 1.5 % of patients.•Type of particle therapy had no effect on overall survival or progression free survival.
To investigate the toxicity and survival outcomes of proton and carbon ion radiotherapy for patients with operable early-stage lung cancer who are eligible for lobectomy.
This multicenter nationwide prospective cohort study included patients with operable early-stage lung cancer. Proton and carbon ion radiotherapy was performed according to the schedule stipulated in the unified treatment policy. Progression-free survival (PFS), overall survival (OS) and treatment-related toxicities were evaluated.
A total of 274 patients were enrolled and included in efficacy and safety analyses. The most common tumor type was adenocarcinoma (44 %), while 105 cases (38 %) were not histologically confirmed or diagnosed clinically. Overall, 250 (91 %) of the 274 patients had tumors that were peripherally situated, while 138 (50 %) and 136 (50 %) patients were treated by proton and carbon ion radiotherapy, respectively. The median follow-up time for all censored patients was 42.8 months (IQR 36.7–49.0). Grade 3 or severe treatment-related toxicity was observed in 4 cases (1.5 %). Three-year PFS was 80.5 % (95 % CI: 75.7 %–85.5 %) and OS was 92.5 % (95 % CI: 89.3 %–95.8 %). Pathological confirmation and clinical stage were factors significantly associated with PFS, while tumor location and particle-ion type were not. Meanwhile, clinical stage was significantly associated with OS, but pathological confirmation, tumor location, and particle-ion type were not.
Particle therapy for operable early-stage lung cancer resulted in excellent 3-year OS and PFS in each subset. In this disease context, proton and carbon ion beam therapies are feasible alternatives to curative surgery.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>38901770</pmid><doi>10.1016/j.radonc.2024.110385</doi><orcidid>https://orcid.org/0000-0002-8529-5420</orcidid><orcidid>https://orcid.org/0000-0002-0626-8142</orcidid><orcidid>https://orcid.org/0000-0001-5276-3665</orcidid><orcidid>https://orcid.org/0000-0002-4431-8892</orcidid><orcidid>https://orcid.org/0000-0002-4037-1688</orcidid><orcidid>https://orcid.org/0000-0001-9809-9800</orcidid><orcidid>https://orcid.org/0000-0001-6450-3027</orcidid><orcidid>https://orcid.org/0000-0002-4947-7665</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-8140 |
| ispartof | Radiotherapy and oncology, 2024-09, Vol.198, p.110385, Article 110385 |
| issn | 0167-8140 1879-0887 1879-0887 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3070839139 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Carbon Female Heavy Ion Radiotherapy - adverse effects Heavy Ion Radiotherapy - methods Humans Lung cancer Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - radiotherapy Male Middle Aged National registry Neoplasm Staging Operable Particle therapy Prospective Studies Proton Proton Therapy - adverse effects Proton Therapy - methods Radiotherapy Registries |
| title | Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A11%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proton%20and%20carbon%20ion%20radiotherapy%20for%20operable%20early-stage%20lung%20cancer;%20a%20prospective%20nationwide%20registry&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Harada,%20Hideyuki&rft.date=2024-09&rft.volume=198&rft.spage=110385&rft.pages=110385-&rft.artnum=110385&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/j.radonc.2024.110385&rft_dat=%3Cproquest_cross%3E3070839139%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3070839139&rft_id=info:pmid/38901770&rft_els_id=S0167814024006558&rfr_iscdi=true |